ArticleWorld journal of surgical oncology2026
The lncRNA OTX2-AS1 promotes NSCLC progression via the miR-377-5p/EIF5A2 axis and EMT induction.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA ACTA2-AS1 acts as a bladder cancer prognostic biomarker and blocks malignant advance via miR-148b-3p/DNAJB4.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe prognosis for non-small cell lung cancer (NSCLC) remains poor, and its underlying molecular mechanisms require further elucidation. This study aimed to systematically investigate the clinical significance, biological function, and potential molecular mechanism of long non‑coding RNA OTX2-AS1 in NSCLC.
methodsOTX2-AS1 expression was examined in a clinical cohort comprising 111 NSCLC patients, and its correlation with clinicopathological characteristics and prognosis was analyzed. OTX2-AS1 expression was modulated in cancer cells via transfection, and its impact on malignant behaviors was assessed using cell counting kit‑8, Transwell, and flow cytometry assays. The direct interactions within the OTX2-AS1/miR-377-5p/eukaryotic translation initiation factor 5A2 (EIF5A2) axis were verified by dual-luciferase reporter and RNA immunoprecipitation experiments.
resultOTX2-AS1 was significantly upregulated in NSCLC tissues and cell lines. Its elevated expression independently correlated with unfavorable patient prognosis. In vitro functional assays confirmed that OTX2-AS1 knockdown inhibited cell viability and invasion while promoting apoptosis in NSCLC cells. Mechanistically, OTX2-AS1 functioned as a molecular sponge to directly sequester miR-377-5p, which in turn targeted and regulated the oncogene EIF5A2. Inhibiting miR-377-5p reversed the anti-tumor effects induced by OTX2-AS1 knockdown, whereas silencing EIF5A2 counteracted the tumor-promoting effects of miR-377-5p inhibition. Activation of this axis upregulated EIF5A2, subsequently suppressing E-cadherin and promoting N-cadherin expression.
conclusionThis study suggests that OTX2-AS1 may promote NSCLC progression by sponging miR-377-5p, leading to EIF5A2upregulation and potential induction of epithelial‑mesenchymal transition. The OTX2-AS1/miR-377-5p/EIF5A2 axis may serve as a potential prognostic biomarker and therapeutic target for NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.